La Jolla Pharmaceutical Company (LJPC) was Initiated by SunTrust to “Buy” and the brokerage firm has set the Price Target at $30. SunTrust advised their investors in a research report released on Jun 22, 2016.
Many Wall Street Analysts have commented on La Jolla Pharmaceutical Company. Lake Street Initiated La Jolla Pharmaceutical Company on May 24, 2016 to “Buy”, Price Target of the shares are set at $25.
La Jolla Pharmaceutical Company opened for trading at $17.49 and hit $17.77 on the upside on Monday, eventually ending the session at $17.33, with a gain of 0.12% or 0.02 points. The heightened volatility saw the trading volume jump to 1,23,621 shares. Company has a market cap of $316 M.
In a different news, on Sep 30, 2015, Lakhmir S Chawla (Chief Medical Officer) purchased 485 shares at $27.75 per share price. According to the SEC, on May 15, 2015, Saiid Zarrabian (director) purchased 307 shares at $19.50 per share price. On May 13, 2015, George F Tidmarsh (CEO) purchased 4,000 shares at $18.37 per share price, according to the Form-4 filing with the securities and exchange commission.
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. Its four product candidates in development include LJPC-501 GCS-100 LJPC-1010 and LJPC-401. LJPC-501 is its formulation of angiotensin for the treatment of catecholamine-resistant hypotension (CRH). GCS-100 is its galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010 is its galectin-3 inhibitor. LJPC-401 is its formulation of hepcidin for the potential treatment of conditions characterized by iron overload such as hemochromatosis and beta thalassemia.